A Trial of Behavioral Intervention on Prognostic Survival of Patients With Unresectable Liver Cancer

NCT07337031 · tracked via the Priya Life Science China tracker

Sponsor

Eastern Hepatobiliary Surgery Hospital

Phase

Not applicable

Started

2026-01

Last updated

2026-01-13

Condition(s) studied

Primary Hepatocellular CarcinomaUnresectable Liver Cancer

Investigational drug(s) / intervention(s)

complex behavioral intervention

complex behavioral intervention: Including behavioral intervention measures such as alcohol cessation management, smoking cessation and respiratory function training, nutrition management, exercise management, blood sugar and weight management, sleep management, pain management, wound and infection management, mindfulness meditation and mental health management.

Study summary

Research purpose

1. To evaluate the impact of complex behavioral intervention on the one-year overall survival rate of patients with unresectable liver cancer after comprehensive treatment, a comparative study was conducted between the complex behavioral intervention group and the standard medical care control group, and the dose-response relationship between the intervention intensity and clinical outcomes was explored.
2. Analyze the impact mechanisms of complex behavioral interventions on patients' quality of life, adverse treatment reactions, and key biological indicators, including evaluating clinical outcomes such as 2-year overall survival rate, progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR), as well as the association between changes in related biomarkers and behavioral compliance.
3. Evaluate the implementation effect and sustainability of the "in-hospital face-to-face + wechat platform" hybrid intervention model, including intervention acceptance, long-term behavior maintenance, health economic benefits, and perioperative recovery of patients undergoing down-conversion surgery.

Eligibility

Sex

ALL

Min age

18 Years

Max age

75 Years

Healthy volunteers

Inclusion Criteria: 1. Pathologically or radiologically confirmed primary hepatocellular carcinoma; 2. BCLC stage B-C, initially assessed as unresectable; 3. Age 18-75 years; 4. ECOG performance status score 0-2; 5. Child-Pugh classification grade A or B (\<=9 points); 6. Normal cognitive ability, capable of understanding and following intervention protocols; 7. Both the patient and primary caregiver can use a smartphone and the WeChat platform and are able to complete questionnaires and follow-up tasks; 8. Voluntarily participates in the study and signs the informed consent form. Exclusion Criteria: 1. Presence of malignant tumors in other organs; 2. Presence of extrahepatic metastasis; 3. Presence of any of the following severe organic diseases in any organ: (1) Cardiovascular: NYHA class III-IV heart failure, acute coronary syndrome within the past 6 months; (2) Liver: Child-Pugh class C cirrhosis, or ALT/AST \>5 times the upper limit of normal; (3) Kidney: eGFR \<45 mL/min/1.73m\^2 or dialysis-dependent; (4) Respiratory: respiratory failure requiring long-term oxygen therapy; (5) Hematologic: hemoglobin \<9 g/dL or platelets \<75×10\^9/L; 4. History of psychiatric disorders, severe cognitive impairment, or substance abuse; 5. Previous liver transplantation or treatment for malignant liver tumors; 6. Complete thrombosis of the main portal vein; 7. Female patients who are pregnant or breastfeeding; 8. Presence of severe congenital or acquired immunodeficiency; 9. Unwillingness to sign the informed consent form; 10. Other conditions deemed unsuitable for participation in this study by the investigator.

Primary outcome measure(s)

Overall survival rate — The time from enrollment to death caused by any reason, mainly the one-year survival rate

Trial sites (1)

Facility	City	Region	Status
Eastern Hepatobiliary Surgery Hospital	Shanghai	China

More Eastern Hepatobiliary Surgery Hospital trials in China

QL1706 Combined With Lenvatinib and GEMOX as First - Line Treatment for Unresectable Biliary Tract Tumors Active, not recruiting

Drug Sensitivity Testing-Based Tumor Organoids to Guide Adjuvant Therapy After Hepatectomy for Primary Liver Cancer Starting soon

HAIC Combined With Immune Therapy for Advanced, Non-Resectable ICC Recruiting

A Clinical Study of Multi-target Hi-TCR-T Cells in the Treatment of Advanced Hepatocellular Carcinoma Recruiting

Efficacy and Safety of SBRT Plus Gemcitabine, Cisplatin, and Sintilimab as First-Line Treatment for Unresectable Biliary Tract Cancer Starting soon

Other trials for the same condition

29-Gene Liver Cancer Subtype and Immunotherapy Effectiveness Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07337031 on ClinicalTrials.gov ↗ ← All trials in China